PhaseBio Pharmaceuticals, Inc. (PHASQ)

NASDAQ: PHASQ · IEX Real-Time Price · USD
0.0701
-0.0249 (-26.21%)
At close: Nov 2, 2022 3:00 PM
0.0533
-0.0168 (-23.97%)
After-hours: Nov 2, 2022 6:56 PM EST
Market Cap 2.34M
Revenue (ttm) 818,000
Net Income (ttm) -102.84M
Shares Out 49.86M
EPS (ttm) -2.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close 0.095
Day's Range 0.0701 - 0.0701
52-Week Range n/a
Beta 2.58
Analysts Sell
Price Target 1.02
Earnings Date Nov 28, 2022

About PHASQ

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary art... [Read more]

Industry Biotechnology
IPO Date Oct 18, 2018
CEO Jonathan Mow
Employees 60
Stock Exchange OTCMKTS
Ticker Symbol PHASQ
Full Company Profile

Analyst Forecast

According to 9 analysts, the average rating for PHASQ stock is "Sell." The 12-month stock price forecast is 1.02, which is a change of from the latest price.

Price Target
$1.02
Analyst Consensus: Sell
Stock Forecasts

News

PhaseBio Pharmaceuticals (PHAS) Reports Q2 Loss, Lags Revenue Estimates

PhaseBio Pharmaceuticals (PHAS) delivered earnings and revenue surprises of -3.03% and 91.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights

3 months ago - Business Wire

PhaseBio Pharmaceuticals (PHAS) Reports Q1 Loss, Misses Revenue Estimates

PhaseBio Pharmaceuticals (PHAS) delivered earnings and revenue surprises of 65.67% and 98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies f...

6 months ago - Business Wire

PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab

6 months ago - Business Wire

PhaseBio Pharmaceuticals to Participate in the 21st Annual Needham Healthcare Conference

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals to Participate in the 21st Annual Needham Healthcare Conference

7 months ago - Business Wire

PhaseBio Announces Positive Results from Phase 2b Trial for Bentracimab

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Announces Positive Results from Phase 2b Trial for Bentracimab

8 months ago - Business Wire

PhaseBio Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Hig...

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #Bentracimab--PhaseBio Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights

8 months ago - Business Wire

PhaseBio Pharmaceuticals Announces Bentracimab Manufacturing Update

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Pharmaceuticals Announces Bentracimab Manufacturing Update

8 months ago - Business Wire

PhaseBio Pharmaceuticals to Participate in the Cowen 42nd Annual Health Care Conference

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Pharmaceuticals to Participate in the Cowen 42nd Annual Health Care Conference

9 months ago - Business Wire

PhaseBio Announces Bentracimab Phase 2b Trial Data Accepted for Late Breaking Clinical Research Presentation at the 2...

MALVERN, PA & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #ACC22--PhaseBio Announces Bentracimab Phase 2b Trial Data Accepted for Late Breaking Clinical Research Presentation at 2022 ACC Annual Scientific Session

9 months ago - Business Wire

PhaseBio Pulls Plug On Mid-Stage Hypertension Asset

PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) is voluntarily ending its Phase 2b trial of pemziviptadil (PB1046) in pulmonary arterial hypertension (PAH). The decision follows COVID-19 impacts on manufact...

11 months ago - Benzinga

PhaseBio Provides Pemziviptadil (PB1046) Program Update

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Provides Pemziviptadil (PB1046) Program Update

11 months ago - Business Wire

PhaseBio Announces Publication of Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab in NEJM Evidence

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #NEJM--PhaseBio Announces Publication of Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab in NEJM Evidence

1 year ago - Business Wire

PhaseBio Names Jonathan Birchall as Chief Commercial Officer

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Names Jonathan Birchall as Chief Commercial Officer

1 year ago - Business Wire

PhaseBio (PHAS) Dips on Mixed Data From Antiplatelet Drug Study

PhaseBio's (PHAS) phase III study evaluating bentracimab for the reversal of antiplatelet effects of ticagrelor meets primary endpoint. The stock falls on high rates of the drug's side effects.

1 year ago - Zacks Investment Research

PhaseBio's Shares Slide As Antiplatelet Candidate Shows Higher Rates Of Side Effect

PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) has announced interim results from the REVERSE-IT Phase 3 trial of bentracimab to reverse the antiplatelet effects of ticagrelor. The trial included patients ...

1 year ago - Benzinga

PhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab for the Reversal of Antiplate...

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ti...

1 year ago - Business Wire

PhaseBio Pharmaceuticals (PHAS) Reports Q3 Loss, Lags Revenue Estimates

PhaseBio Pharmaceuticals (PHAS) delivered earnings and revenue surprises of -6.45% and -87.43%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the s...

1 year ago - Zacks Investment Research

PhaseBio Reports Third-Quarter 2021 Financial Results and Recent Business Highlights

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Reports Third-Quarter 2021 Financial Results and Recent Business Highlights

1 year ago - Business Wire

PhaseBio Pharmaceuticals to Host Investor Call to Discuss Interim Results from Pivotal REVERSE-IT Phase 3 Trial Prese...

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #AHA2021--PhaseBio Pharmaceuticals to Host Investor Call to Discuss Interim Results from Pivotal REVERSE-IT Phase 3 Trial Presented at AHA Annual Meeting

1 year ago - Business Wire

PhaseBio's Bentracimab Reverses Ticagrelor-Associated Antiplatelet Activity In Mid-Stage Study

PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) has announced topline data from its Phase 2b trial of bentracimab in healthy, older volunteers 50-80 years old. The trial in 150 subjects receiving bentracima...

1 year ago - Benzinga

PhaseBio Announces Topline Results From Phase 2b Trial for Bentracimab

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Announces Topline Results from Phase 2b Trial for Bentracimab

1 year ago - Business Wire

Do Options Traders Know Something About PhaseBio Pharmaceuticals (PHAS) Stock We Don't?

Investors need to pay close attention to for PhaseBio Pharmaceuticals (PHAS) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research